Search results for "Gastroenterologia"

showing 10 items of 310 documents

Infliximab in the treatment of Crohn's disease: Predictors of response in an Italian multicentric open study

2005

Abstract Background. Almost 20% of patients with active Crohn's disease are refractory to conventional therapy. Infliximab is a treatment of proven efficacy in this group of patients and it is not clear which variables predict a good response. Aims. To evaluate the role of infliximab looking at the predictors of response in a large series of patients with Crohn's disease. Patients and methods. Five hundred and seventy-three patients with luminal refractory Crohn's disease (Crohn's Disease Activity Index (CDAI) > 220–400) (312 patients) or with fistulising disease (190 patients) or both of them (71 patients) were treated with a dose of 5 mg/kg in 12 Italian referral centres. The primary endp…

AdultMalemedicine.medical_specialtyFistulaPredictors of responseAge at diagnosisDiseaseGastroenterologyAntibodiesDose-Response RelationshipCrohn DiseaseGastrointestinal AgentsRefractoryInternal medicineMonoclonalmedicineHumansinfliximab.crohn's disease.Settore MED/12 - GastroenterologiaCrohn's diseaseDose-Response Relationship DrugHepatologybusiness.industryRemission InductionSmokingGastroenterologyAntibodies Monoclonalmedicine.diseaseCrohn's Disease Activity IndexInfliximabInfliximabSurgeryOpen studyCrohn's diseaseCrohn's disease; Infliximab; Predictors of response; Adult; Antibodies Monoclonal; Crohn Disease; Dose-Response Relationship Drug; Female; Fistula; Gastrointestinal Agents; Humans; Infliximab; Italy; Male; Multivariate Analysis; Remission Induction; SmokingItalyConcomitantMultivariate AnalysisFemaleCrohn's disease; Infliximab; Predictors of responseDrugbusinessmedicine.drugDigestive and Liver Disease
researchProduct

An open-safety study of dual antiviral therapy in real-world patients with chronic hepatitis C

2010

Purpose Treatment of patients with chronic hepatitis C with alpha-interferon and ribavirin usually produces adverse events within the first 3 months. We aimed to assess safety and predictors of discontinuation or dose modification of these drugs. Methods Observational study of 312 patients with predominantly genotype 1 chronic hepatitis C treated openly along 5 years in a clinical practice setting. Results Eighty-four percent of patients experienced at least one adverse event (853 events in total, 3.3 per patient on average). Incidence rate was higher during the first 90 days and decreased thereafter (<5%). Discontinuation rates at 30 and 90 days and at end of treatment were 2, 4 and 8%, re…

AdultMalemedicine.medical_specialtyGenotypeEpidemiologyadverse eventHepacivirusAntiviral AgentsSettore MED/01 - Statistica MedicaMedication Adherencechemistry.chemical_compoundChronic hepatitisInternal medicineRibavirinHumansMedicinePharmacology (medical)Dual therapyAdverse effectDose ModificationSettore MED/12 - GastroenterologiaDose-Response Relationship Drugbusiness.industryIncidenceRibavirinAge FactorsAntiviral therapyInterferon-alphainterferonpredictionHepatitis CHepatitis C ChronicMiddle Agedmedicine.diseaseSurgeryDiscontinuationchemistryDrug Therapy CombinationFemalehepatitis CbusinessPharmacoepidemiology and Drug Safety
researchProduct

Retinol-binding protein 4: a new marker of virus-induced steatosis in patients infected with hepatitis C virus genotype 1.

2008

Retinol-binding protein 4 (RBP4) is an adipocytokine associated with insulin resistance (IR). We tested serum levels of RBP4 to assess its link with steatosis in patients with genotype 1 chronic hepatitis C (CHC) or nonalcoholic fatty liver disease (NAFLD). Nondiabetic patients with CHC (n = 143) or NAFLD (n = 37) were evaluated by liver biopsy and anthropometric and metabolic measurements, including IR by the homeostasis model assessment. Biopsies were scored by Scheuer classification for CHC, and Kleiner for NAFLD. Steatosis was tested as a continuous variable and graded as absent-mild &lt;30%, or moderate-severe &gt; or =30%. Thirty nondiabetic, nonobese blood donors served as controls. …

AdultMalemedicine.medical_specialtyGenotypeHepatitis C virusHepacivirusSettore MED/08 - Anatomia Patologicamedicine.disease_causeGastroenterologySeverity of Illness IndexInsulin resistanceRisk FactorsInternal medicineNonalcoholic fatty liver diseasemedicinesteatosisHumansRetinol-binding protein 4 .Retinol binding protein 4Settore MED/12 - GastroenterologiaHepatologybiologymedicine.diagnostic_testOdds ratioHepatologyHepatitis C ChronicMiddle Agedmedicine.diseaseFatty LiverLogistic ModelsLiverLiver biopsyImmunologybiology.proteinFemaleSteatosisRetinol-Binding Proteins PlasmaBiomarkers
researchProduct

High liver RBP4 protein content is associated with histological features in patients with genotype 1 chronic hepatitis C and with nonalcoholic steato…

2011

Abstract Background and aim To investigate the hepatic expression of retinol-binding protein-4 (RBP4) in chronic hepatitis C (CHC) and nonalcoholic steatohepatitis (NASH) patients, and its association with biochemical and histological patterns of liver damage. Materials and methods Sixty-six genotype 1 CHC and 32 NASH patients were tested for hepatic RBP4 expression. Liver expression at immunostaining was scored as 0 (slight), 1 (mild), 2 (moderate), and 3 (intense). In addition, the mRNA and the quantitative protein expressions of RBP4 were tested by PCR and by western blot, respectively, in 12 NASH and 28 CHC patients. Twelve subjects undergoing elective cholecystectomy served as controls…

AdultMalemedicine.medical_specialtyLogistic ModelFibrosiHepatitis C virusInflammationSettore MED/08 - Anatomia Patologicamedicine.disease_causeGastroenterologyBody Mass IndexWestern blotFibrosisNon-alcoholic Fatty Liver DiseaseInternal medicineGenotypeMedicineHumansAge FactorRNA MessengerHEPATIC STEATOSISRetinol binding protein 4Settore MED/12 - GastroenterologiaHepatologymedicine.diagnostic_testbiologyNONALCOHOLIC STEATOHEPATITISbusiness.industryGastroenterologyAge FactorsHEPATITIS C VIRUSHepatitis C ChronicMiddle Agedmedicine.diseaseFibrosisFatty LiverLogistic Modelsbiology.proteinmedicine.symptomSteatosisInsulin ResistanceWaist CircumferenceRetinol binding protein-4businessRetinol-Binding Proteins PlasmaImmunostainingHumanDigestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
researchProduct

Inflammatory Bowel Disease Phenotype as Risk Factor for Cancer in a Prospective Multicentre Nested Case-Control IG-IBD Study

2016

Background and Aims: Cancer risk in inflammatory bowel disease [IBD] is still debated. In a prospective, multicentre, nested case-control study, we aimed to characterise incident cases of cancer in IBD. The role of immunomodulators vs clinical characteristics of IBD as risk factors for cancer was also investigated. Materials and Methods: From January 2012 to December 2014, each IBD patient with incident cancer was matched with two IBD patients without cancer for: IBD type, gender, and age. Risk factors were assessed by multivariate regression analysis. Results: IBD patients considered numbered 44619: 21953 Crohn’s disease \[CD], 22666 ulcerative colitis [UC]. Cancer occurred in 174 patients…

AdultMalemedicine.medical_specialtyPancolitisAdolescentColorectal cancerphenotypeSettore MED/12 - GASTROENTEROLOGIAcancer riskInflammatory bowel disease; cancer risk; phenotype; Adolescent; Adult; Aged; Aged 80 and over; Case-Control Studies; Female; Follow-Up Studies; Humans; Immunologic Factors; Incidence; Inflammatory Bowel Diseases; Logistic Models; Male; Middle Aged; Multivariate Analysis; Neoplasms; Prospective Studies; Risk Factors; Young Adult; PhenotypeGastroenterologyInflammatory bowel diseaseInflammatory bowel disease03 medical and health sciencesYoung Adult0302 clinical medicineRisk FactorsInternal medicineNeoplasms80 and overmedicineHumansImmunologic FactorsProspective StudiesRisk factorProspective cohort studyAgedAged 80 and overbusiness.industryIncidenceSettore MED/09 - MEDICINA INTERNAGastroenterologyCancerGeneral MedicineMiddle Agedmedicine.diseaseInflammatory Bowel DiseasesUlcerative colitisLogistic Models030220 oncology & carcinogenesisCase-Control StudiesNested case-control studyMultivariate Analysis030211 gastroenterology & hepatologyFemalemedicine.symptombusinessInflammatory bowel disease; cancer risk; phenotypeFollow-Up Studies
researchProduct

Different doses of consensus interferon plus ribavirin in patients with hepatitis C virus genotype 1 relapsed after interferon monotherapy: a randomi…

2006

AIM: To assess the efficacy of different schedules of consensus interferon (CIFN) plus ribavirin in retreating chronic hepatitis C patients who relapsed after recombinant interferon (rIFN) monotherapy. METHODS: Forty-five patients (34 males and 11 females) with chronic hepatitis due to hepatitis C virus (HCV) genotype 1 who relapsed after a previous course of rIFN monotherapy were randomized to receive 9 μg CIFN three times per week for 52 wk (group A, n = 22) or 18 μg CIFN three times per week for 52 wk (group B, n = 23) in combination with ribavirin 800 to 1200 mg daily for 52 wk (according to body weight). Virological response was evaluated at week 24 (EVR), at the end of treatment (ETR)…

AdultMalemedicine.medical_specialtySettore MED/07 - Microbiologia E Microbiologia ClinicavirusesHepacivirusAlpha interferonHepacivirusPharmacologyGastroenterologyAntiviral AgentsDrug Administration Schedulelaw.inventionchemistry.chemical_compoundRandomized controlled triallawInterferonRecurrenceInternal medicineRibavirinmedicineHumansIn patientSettore MED/12 - GastroenterologiabiologyDose-Response Relationship Drugbusiness.industryRibavirinGastroenterologyInterferon-alphaGeneral MedicineHepatitis C ChronicMiddle AgedViral Loadbiology.organism_classificationhumanitiesRecombinant ProteinsTreatment OutcomechemistryInterferon Type IInterferon Ribavirin Hepatitis C virus Hepatitis C RelapserDrug Therapy CombinationFemalebusinessViral loadInterferon type IRapid Communicationmedicine.drugWorld journal of gastroenterology
researchProduct

Esophageal Motility Changes after Thyroidectomy; Possible Associations with Postoperative Voice and Swallowing Disorders: Preliminary Results

2013

Objective Swallowing and voice impairment are common after thyroidectomy. We evaluated short-term functional changes in esophageal motility in a series of patients who had undergone total thyroidectomy. Several studies have investigated these symptoms by means of interviews or questionnaires. Study Design Prospective study. Setting Academic research. Materials and Methods Thirty-six consenting patients were prospectively recruited. Eligibility criteria were thyroid volume ≤60 mL, benign disease, and age between 18 and 65 years. Exclusion criteria were previous neck surgery, severe thyroiditis, hyperthyroidism, and pre- or postoperative vocal cord palsy. Voice impairment score, swallowing im…

AdultMalemedicine.medical_specialtyTime FactorsManometrymedicine.medical_treatmentComorbidityAudiologyRisk AssessmentSeverity of Illness IndexStatistics NonparametricCohort StudiesYoung AdultAge DistributionmedicineHumansEsophageal Motility DisordersProspective StudiesSex Distributiondysphagia thyroidectomy voice impairmentAgedVoice impairmentSettore MED/12 - GastroenterologiaVoice Disordersbusiness.industryIncidenceSwallowing DisordersThyroidectomyMiddle AgedThyroid DiseasesSettore MED/45 - Scienze Infermieristiche Generali Cliniche E PediatricheSettore MED/18 - Chirurgia GeneraleSettore MED/31 - OtorinolaringoiatriaItalyOtorhinolaryngologyAnesthesiaThyroidectomyFemaleSurgeryDeglutition DisordersbusinessEsophageal motilityFollow-Up StudiesOtolaryngology–Head and Neck Surgery
researchProduct

Fluoroquinolone-induced liver injury: three new cases and a review of the literature.

2012

PURPOSE: Fluoroquinolones are popular and widely used in primary care and hospital settings. Premarketing studies showed a favourable side-effect profile. However, significant morbidity and the need for liver transplantation for acute liver failure have been reported. We reviewed the available data on liver damage linked to fluoroquinolones. METHODS: A systematic search of case reports on the MEDLINE database encompassing the years 2000-2011 was carried out. Additional references were found by a manual search of the retrieved paper. We also describe three new cases of hepatotoxicity attributable to fluoroquinolones seen at our Unit. RESULTS: Thirty-five cases were retrieved from MEDLINE (51…

AdultMalemedicine.medical_specialtymedicine.medical_treatmentTreatment outcomePrimary careLiver transplantationfluoroquinoloneSeverity of Illness IndexSeverity of illnessMedicineHumansPharmacology (medical)Liver damageIntensive care medicinePharmacologyHepatitisLiver injurySettore MED/12 - Gastroenterologiabusiness.industryLiver failureGeneral MedicineMiddle Agedmedicine.diseaseAnti-Bacterial AgentsTreatment OutcomeItalyliver damageSettore BIO/14 - FarmacologiaFemaleDILIChemical and Drug Induced Liver InjurybusinessFluoroquinolones
researchProduct

Retrospective, observational, multicentre study on an Italian population affected by chronic hepatitis C who failed to clear HCV-RNA after the combin…

2010

There is a lack of information on the characteristics of patients with chronic hepatitis C virus infection (HCV) who fail to respond to antiviral treatment. We studied HCV-positive subjects with chronic liver diseases treated with pegylated-interferon (PEG-IFN) and ribavirin (RBV) who failed to clear HCV in routine clinical practice. A total of 2150 consecutive adult patients treated with PEG-IFN plus RBV therapy in 46 Italian centres between 1 July 2004, and 30 June 2005, were studied. Of the 2150 patients, 923 (42.9%) (M/F 585/335, mean age 54.8 years) failed to achieve a serum HCV-RNA clearance. Of these 923 patients, 429 (46.5%) were nonresponders, 298 (32.3%) relapsers, 168 (18.2%) dro…

AdultMalenon-responders.relapserGenotypebody mass index; cirrhosis; hepatitis c virus; nonresponder; pegylated-interferon; relapserInfectious Diseasebody mass indexHepacivirusvirusInterferon alpha-2Antiviral AgentsPolyethylene GlycolPolyethylene GlycolsMedication Adherencebody mass index; cirrhosis; hepatitis C; virus; nonresponder; pegylated-interferon; relapserRisk FactorsRetrospective StudienonresponderVirologyRibavirinHumansAge FactorTreatment FailureRetrospective StudiesAgedAntiviral AgentSettore MED/12 - GastroenterologiaHCV; Antiviral therapy; Body mass index; Cirrhosis; Hepatitis C virus; Nonresponder; Pegylated-interferon; RelapserCirrhosiHepaciviruHepatologyRisk FactorcirrhosisAge FactorsInterferon-alphahepatitis c virusHepatitis C ChronicMiddle AgedRecombinant ProteinRecombinant ProteinsItalyRNA ViralFemalehepatitis Cpegylated-interferonHepatitis C viruHuman
researchProduct

Appropriateness guidelines and predictive rules to select patients for upper endoscopy: a nationwide multicenter study.

2010

OBJECTIVES: Selecting patients appropriately for upper endoscopy (EGD) is crucial for efficient use of endoscopy. The objective of this study was to compare different clinical strategies and statistical methods to select patients for EGD, namely appropriateness guidelines, age and/or alarm features, and multivariate and artificial neural network (ANN) models. METHODS: A nationwide, multicenter, prospective study was undertaken in which consecutive patients referred for EGD during a 1-month period were enrolled. Before EGD, the endoscopist assessed referral appropriateness according to the American Society for Gastrointestinal Endoscopy (ASGE) guidelines, also collecting clinical and demogra…

AdultMaleupper endoscopymedicine.medical_specialtyPediatricsAppropriateness Upper EndoscopyAdolescentCross-sectional studySettore MED/12 - GASTROENTEROLOGIADigestive System DiseasesMEDLINEappropriatnessYoung Adultappropriatness; upper endoscopy; multicenter studymedicineHumansEndoscopy Digestive SystemProspective StudiesProspective cohort studyAgedAged 80 and overHepatologymedicine.diagnostic_testbusiness.industryEsophagogastroduodenoscopyPatient SelectionUpper endoscopyGastroenterologyNeural Networks (Computer)Middle AgedEndoscopyClinical trialSettore MED/18 - Chirurgia Generalemulticenter studyCross-Sectional StudiesLogistic ModelsMulticenter studyItalyROC CurveEmergency medicinePractice Guidelines as TopicFemaleNeural Networks ComputerbusinessThe American journal of gastroenterology
researchProduct